Indication

Galliprant controls pain and inflammation associated with osteoarthritis in dogs.

Important Safety Information

For use in dogs only. Keep this and all medications out of reach of children and pets to prevent accidental ingestion or overdose. Galliprant is a non-COX inhibiting NSAID. As a class, NSAIDs may be associated with gastrointestinal, kidney and liver side effects. Evaluation for pre-existing conditions and regular monitoring are recommended. Do not use in dogs that have a hypersensitivity to grapiprant. Concomitant use of Galliprant with other NSAIDs or corticosteroids should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. Owners should be advised to observe for signs of potential drug toxicity. Adverse reactions may include vomiting, diarrhea, decreased appetite, watery or bloody stools, and decreases in serum albumin and total protein. Please see product label or visit my.elanco.com/us/galliprant for full prescribing information.

About Elanco

Learn why we're a leading provider of innovative solutions that protect and enhance animal health.

Connect with Elanco

Galliprant, Elanco, and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-25-0545(3)

© 2025 Elanco or its affiliates.